Doctors can now tailor interventional oncology treatment to better meet patient needs
March 25, 2012
/PRNewswire/ - Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, today launched a new custom dose feature in
for TheraSphere®, Nordion's
microsphere treatment for liver cancer. Nordion has also filed a request with the Food and Drug Administration for approval of the custom dose feature in
the United States
In addition to standard dose vial configurations, Nordion now offers an expanded range of TheraSphere treatment options with custom doses available in wider variety of increments. The custom doses are designed to provide greater treatment flexibility for physicians, save administration time and reduce product waste, while limiting unnecessary radiation exposure to patients and healthcare professionals.
Nordion has also enhanced its Treatment Window Illustrator tool to demonstrate how custom doses can be selected and compared to standard dose vial configurations.
Nordion is attending the Society of Interventional Radiology (SIR) Annual Scientific Meeting 2012,
. Nordion representatives will be at
to talk about TheraSphere to physicians attending the conference. Nordion will host two "Eat and Be Educated" learning sessions at its booth:
Sunday, March 25, 12:15pm
Glass Microspheres Fits in Our Treatment Algorithm
, MD Professor of Radiology and Surgery
Indiana University School of Medicine
Tuesday March 27, 12:15pm
TheraSphere Multi-Vessel Delivery
, MD Assistant Professor, Interventional Radiologist
University of Washington
- Harbourview Medical Center
Each session will be followed by a Nordion presentation on how to start a TheraSphere program.